Global B2B Pharmaceutical Marketplace · Sourcing · Named-Patient Access
💬 WhatsApp · Sign in · Register
RECOMBINANT HUMAN EPIDERMAL GROWTH FACTOR GEL bulk supplier for pharma manufacturers

Recombinant Human Epidermal Growth Factor Gel 60MCG, 150 mcg Suppliers & Bulk Manufacturers

Available Forms: Gel

Available Strengths: 60MCG, 150 mcg

Reference Brands: Regen-D (India), Epifast (LATAM)

Category: Medical Aid

Gel contains Recombinant Human Epidermal Growth Factor. It is used to treat first and second-degree burns. It is used to heal the scars of the skin grafts. Burns may be caused by accidental contact with fire, chemicals, electricity, or excessive sun exposure.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

📘 Sourcing Guide

Product Description:

First-degree burn involves the superficial layer of the skin resulting in redness and pain. Second-degree burn affects 1st and 2nd layer of skin (epidermis and dermis), which may result in redness, blisters, severe pain, or scarring.

Recombinant Human Epidermal Growth Factor (rhEGF) Gel is a bioengineered form of the naturally occurring human epidermal growth factor, a polypeptide that plays an essential role in the regulation of cell growth, proliferation, and tissue repair. Produced using recombinant DNA technology, rhEGF is designed to support epithelial regeneration and enhance the body’s natural wound-healing processes.

When applied topically, rhEGF stimulates epithelial cell proliferation, differentiation, and migration, which helps accelerate the regeneration of damaged skin and tissues. This mechanism promotes faster wound closure and improves overall healing outcomes in various types of skin injuries. Recombinant Human Epidermal Growth Factor Gel is widely used in the management of chronic wounds such as diabetic foot ulcers, burns, surgical wounds, and other skin lesions that require enhanced tissue repair.

In addition to its regenerative effects, rhEGF may also provide cytoprotective benefits by helping to reduce epithelial damage associated with chemotherapy or radiotherapy. By supporting healthy cell growth and tissue recovery, Recombinant Human Epidermal Growth Factor Gel serves as an important therapeutic option in advanced wound care and dermatological treatment.

Recombinant Human Epidermal Growth Factor Gel — third party manufacturing & bulk supply

Recombinant Human Epidermal Growth Factor Gel 60MCG, 150 mcg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.
Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.
Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

What to include when you enquire

  • Destination market — determines which manufacturers hold the right site-level approvals
  • First order quantity and estimated annual volume
  • Whether you need a registration dossier or the product is already registered
  • Packaging, labelling and language requirements
  • Incoterms and required shelf life

Manufacturers of Recombinant Human Epidermal Growth Factor Gel listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.

Request a quote for Recombinant Human Epidermal Growth Facto... →
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing

Frequently Asked Questions

Recombinant Human Epidermal Growth Factor (rhEGF) Gel is used to promote wound healing by stimulating the growth and regeneration of skin cells. It is commonly used for the treatment of diabetic foot ulcers, burns, surgical wounds, chronic ulcers, and other skin injuries where faster tissue repair is required.

Recombinant Human Epidermal Growth Factor Gel is produced using recombinant DNA technology. It contains a laboratory-produced form of human epidermal growth factor, a protein that stimulates cell growth, proliferation, and tissue regeneration.

Common trade names include Easyef, Heberprot-P (EGF-based therapy), Regen-D 150, and Epidermal Growth Factor Gel.

This product is manufactured by several pharmaceutical and biotechnology companies including Daewoong Pharmaceutical, Bharat Biotech, and Heber Biotec depending on the specific brand and formulation.

The generic name is recombinant human epidermal growth factor.

Brand names include Easyef (South Korea and international markets), Regen-D 150 (India), and other regional EGF gel formulations available in Asia and Latin America.

Recombinant Human Epidermal Growth Factor Gel is manufactured in several countries including South Korea, India, China, and Cuba depending on the manufacturer and brand.

Related Products

Indocyanine Green

Strength:
25 mg

Form: Injection

Reference Brands: IC-Green (USA), Verdye (USA/EU)

View Details
Hexaminolevulinate Hydrochloride

Strength:
100 mg , 85 mg

Form: Injection

Reference Brands: Cysview (USA), Hexvix (EU)

View Details
Indigotindisulfonate Sodium

Strength:
20 mg/mL, 40 mg/mL

Form: Injection

Reference Brands: Indigo Carmine ((USA), Bludigo (USA)

View Details
Lofexidine Hydrochloride

Strength:
0.18 mg

Form: Tablets

Reference Brands: Lucemyra (USA)

View Details
Enquire Now

Quick Response Guaranteed | Verified Suppliers

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.